ArticleNature communications2020
Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Immune Biomarkers of Islet Transplant Rejection Revealed by Synthetic Immunological Niche.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Synthetic Immunological Niche Reveals Early Immune Dysregulation and Stratifies Therapeutic Response in Type 1 Diabetes.bioRxiv : the preprint server for biology · 2026Article
- Antigen-conjugated scaffolds enable sustained delivery of antigen and enrichment of antigen-specific T-cells.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Longitudinal monitoring of type 1 diabetes progression to disease onset.Science advances · 2026Article
- Don't judge an implant by its cover: how the foreign body response and fibrotic capsule might be harnessed for good.npj biomedical innovations · 2026Review
- Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Immunological microenvironment and targeted therapeutics in multiple sclerosis: new insights in crosstalk between immune niches and CNS.Frontiers in immunology · 2025Review
- Artificial intelligence based advancements in nanomedicine for brain disorder management: an updated narrative review.Frontiers in medicine · 2025Review
- Polymer scaffolds delineate healthy from diseased states at sites distal from the pancreas in two models of type 1 diabetes.Biotechnology and bioengineering · 2024Article
- Engineered Immunologic Niche Monitors Checkpoint Blockade Response and Probes Mechanisms of Resistance.Immunomedicine · 2024Article
- Biomarkers from subcutaneous engineered tissues predict acute rejection of organ allografts.Science advances · 2024Article
- Biomaterial engineering strategies for B cell immunity modulations.Biomaterials science · 2024Review
- The therapeutic potential of immunoengineering for systemic autoimmunity.Nature reviews. Rheumatology · 2024Review
- A synthetic metastatic niche reveals antitumor neutrophils drive breast cancer metastatic dormancy in the lungs.Nature communications · 2023Article
- Targeting L-Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Restoring normal islet mass and function in type 1 diabetes through regenerative medicine and tissue engineering.The lancet. Diabetes & endocrinology · 2021Review
- Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages.Life science alliance · 2021Article
- Exploiting Rational Assembly to Map Distinct Roles of Regulatory Cues during Autoimmune Therapy.ACS nano · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Relapses in multiple sclerosis can result in irreversible nervous system tissue injury. If these events could be detected early, targeted immunotherapy could potentially slow disease progression. We describe the use of engineered biomaterial-based immunological niches amenable to biopsy to provide insights into the phenotype of innate immune cells that control disease activity in a mouse model of multiple sclerosis. Differential gene expression in cells from these niches allow monitoring of disease dynamics and gauging the effectiveness of treatment. A proactive treatment regimen, given in response to signal within the niche but before symptoms appeared, substantially reduced disease. This technology offers a new approach to monitor organ-specific autoimmunity, and represents a platform to analyze immune dysfunction within otherwise inaccessible target tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.